BrainCheck, a cognitive health assessment company founded by Stanford neuroscience professor David Eagleman, scored a $15 million Series B extension, CEO Kim Rodriguez tells Axios exclusively.
Why it matters: The company's tests address a pressing need as the risk of Alzheimer's disease grows.
